Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phase 3 trial. The VIVID-1 ...

American pharmaceutical company Eli Lilly has started selling higher doses of its popular weight-loss drug Zepbound in vials, at a $150 discount to the cost of the injector pen versions.

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab ... 137.35 and $265.20 for a pack of five pens. People who are most likely ...

Lilly said in a statement that patients could buy the Zepbound vials for $499 per month on its LillyDirect website, roughly 23% cheaper than the $650 it charges for its injector pen to insured ...

2 1. FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease. News release. Eli Lilly and Company.

Results showed 92.9% of mirikizumab-treated patients who were ... Commenting on the findings, Mark Genovese, MD, senior vice president of Lilly Immunology development, said: “These results ...

about Omvoh (mirikizumab-mrkz) as a treatment for people with moderate to severe Crohn's disease and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. 2,3 "Many ...